Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer | Zendy

Solange Peters | Zendy; D. Ross Camidge | Zendy; Alice T. Shaw | Zendy; Shirish M. Gadgeel | Zendy; Jin Seok Ahn | Zendy; DongWan Kim | Zendy; SaiHong Ignatius Ou | Zendy; M. Pérol | Zendy; Rafał Dziadziuszko | Zendy; Rafael Rosell | Zendy; Ali Zeaiter | Zendy; Emmanuel Mitry | Zendy; Sophie Golding | Zendy; Bogdana Balas | Zendy; Johannes Noé | Zendy; Peter N. Morcos | Zendy; Tony Mok | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

Author(s) -

Solange Peters,

D. Ross Camidge,

Alice T. Shaw,

Shirish M. Gadgeel,

Jin Seok Ahn,

DongWan Kim,

SaiHong Ignatius Ou,

M. Pérol,

Rafał Dziadziuszko,

Rafael Rosell,

Ali Zeaiter,

Emmanuel Mitry,

Sophie Golding,

Bogdana Balas,

Johannes Noé,

Peter N. Morcos,

Tony Mok

Publication year - 2017

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1704795

Subject(s) - alectinib , crizotinib , medicine , ceritinib , lung cancer , oncology , anaplastic lymphoma kinase , alk inhibitor , clinical endpoint , hazard ratio , progression free survival , survival rate , gastroenterology , randomized controlled trial , confidence interval , chemotherapy , malignant pleural effusion

Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-positive non-small-cell lung cancer (NSCLC). We investigated alectinib as compared with crizotinib in patients with previously untreated, advanced ALK-positive NSCLC, including those with asymptomatic CNS disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research